Vimentin regulates activation of the NLRP3 inflammasome

Nature Communications

Volumn 6, Issue , 2015, Pages

  Dos Santos, Gimena ^a   Rogel, Micah R ^a,b   Baker, Margaret A ^a   Troken, James R ^a   Urich, Daniela ^a   Morales Nebreda, Luisa ^a   Sennello, Joseph A ^a   Kutuzov, Mikhail A ^a   Sitikov, Albert ^a   Davis, Jennifer M ^a   Lam, Anna P ^a   Cheresh, Paul ^a,c   Kamp, David ^a,c   Shumaker, Dale K ^a   Budinger, G R Scott ^a,c   Ridge, Karen M ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BLEOMYCIN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; VIMENTIN; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE;

BLOOD; INJURY; MATURATION; PROTEIN; RESPIRATORY DISEASE; RODENT;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BONE MARROW; CONTROLLED STUDY; FEMALE; FIBROSIS; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; INTERMEDIATE FILAMENT; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; LUNG FIBROSIS; LUNG INJURY; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PROTEIN PROTEIN INTERACTION; ANIMAL; ATOMIC FORCE MICROSCOPY; BONE MARROW CELL; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; KNOCKOUT MOUSE; LUNG; MACROPHAGE; METABOLISM; PATHOLOGY; PROTEIN ANALYSIS;

MURINAE; MUS;

ACUTE LUNG INJURY; ANIMALS; BLEOMYCIN; BONE MARROW CELLS; BRONCHOALVEOLAR LAVAGE FLUID; CARRIER PROTEINS; CELL LINE; CELL PROLIFERATION; FEMALE; FIBROSIS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; LUNG; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MICROSCOPY, ATOMIC FORCE; PROTEIN INTERACTION MAPPING; VIMENTIN;

EID: 84924617839     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7574     Document Type: Article

References (66)

1. Fletcher, D. A. & Mullins, R. D. Cell mechanics and the cytoskeleton. Nature 463, 485-492 (2010).
2. Eriksson, J. E. et al. Introducing intermediate filaments: from discovery to disease. J. Clin. Invest. 119, 1763-1771 (2009).
3. Colucci-Guyon, E. et al. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell 79, 679-694 (1994).
4. Eckes, B. et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J. Cell. Sci. 113, 2455-2462 (2000).
5. Henderson, P., Wilson, D. C., Satsangi, J. & Stevens, C. A role for vimentin in Crohn disease. Autophagy 8, 1695-1696 (2012).
6. Mor-Vaknin, N. et al. Murine colitis is mediated by vimentin. Sci. Rep. 3, 1045 (2013).
7. Song, S. et al. Functions of the intermediate filament cytoskeleton in the eye lens. J. Clin. Invest. 119, 1837-1848 (2009).
8. Omary, M. B. "IF-pathies": a broad spectrum of intermediate filament-associated diseases. J. Clin. Invest. 119, 1756-1762 (2009).
9. Herrmann, H., Strelkov, S. V., Burkhard, P. & Aebi, U. Intermediate filaments: primary determinants of cell architecture and plasticity. J. Clin. Invest. 119, 1772-1783 (2009).
10. Liem, R. K. & Messing, A. Dysfunctions of neuronal and glial intermediate filaments in disease. J. Clin. Invest. 119, 1814-1824 (2009).
11. Ivaska, J., Pallari, H. M., Nevo, J. & Eriksson, J. E. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell. Res. 313, 2050-2062 (2007).
12. Pallari, H. M. & Eriksson, J. E. Intermediate filaments as signaling platforms. Sci. STKE 2006, pe53 (2006).
13. Miller, L. S. et al. Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J. Immunol. 179, 6933-6942 (2007).
14. Cohen, T. S. & Prince, A. S. Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia. J. Clin. Invest. 123, 1630-1637 (2013).
15. Mishra, B. B. et al. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol. 12, 1046-1063 (2010).
16. Allen, I. C. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30, 556-565 (2009).
17. Lamkanfi, M. & Dixit, V. M. The inflammasomes. PLoS Pathog. 5, e1000510 (2009).
18. Lamkanfi, M. & Dixit, V. M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227, 95-105 (2009).
19. Gasse, P. et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Resp. Crit. Care Med. 179, 903-913 (2009).
20. Wynn, T. A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339-1350 (2011).
21. Liu, G., Cheresh, P. & Kamp, D. W. Molecular basis of asbestos-induced lung disease. Annu. Rev. Pathol. 8, 161-187 (2013).
22. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008).
23. Cassel, S. L. et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA 105, 9035-9040 (2008).
24. Bauernfeind, F. et al. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187, 613-617 (2011).
25. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
26. Rathinam, V. A., Vanaja, S. K. & Fitzgerald, K. A. Regulation of inflammasome signaling. Nat. Immunol. 13, 333-342 (2012).
27. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
28. Dos Santos, G., Kutuzov, M. A. & Ridge, K. M. The inflammasome in lung diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 15, L627-L633 (2012).
29. Do-Umehara, H. C. et al. Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-d. Nat. Immunol. 14, 461-469 (2013).
30. Wang, H. L. et al. The intrinsic apoptotic pathway is required for lipopolysaccharide-induced lung endothelial cell death. J. Immunol. 179, 1834-1841 (2007).
31. Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S. &Perlman, H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 49, 503-510 (2013).
32. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody. N. Engl. J. Med. 7, 1018-1028 (2006).
33. Moore, B. B. & Hogaboam, C. M. Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L152-L160 (2008).
34. Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 44, 725-738 (2011).
35. Gasse, P. et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 117, 3786-3799 (2007).
36. Gross, T. J. & Hunninghake, G. W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345, 517-525 (2001).
37. Faffe, D. S. & Zin, W. A. Lung parenchymal mechanics in health and disease. Physiol. Rev. 89, 759-775 (2009).
38. rd J. P. & Martinez, F. J. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 55, 395-417 (2004).
39. Hernandez-Cuellar, E. et al. Cutting edge: nitric oxide inhibits the NLRP3 inflammasome. J. Immunol. 189, 5113-5117 (2012).
40. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
41. Compan, V. et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 37, 487-500 (2012).
42. Shah, N. B. & Duncan, T. M. Bio-layer interferometry for measuring kinetics of protein-protein interactions and allosteric ligand effects. J. Vis. Exp. 84, e51383 (2014).
43. Zinchuk, V., Wu, Y. & Grossenbacher-Zinchuck, O. Briding the gap between qualitative and quantitative colocalization results in fluorescence microscopy studies. Sci. Rep. 3, 1365 (2013).
44. Matthay, M. A., Ware, L. B. & Zimmerman, G. A. The acute respiratory distress syndrome. J. Clin. Invest. 122, 2731-2740 (2012).
45. Dolinay, T. et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am. J. Resp. Crit. Care Med. 185, 1225-1234 (2012).
46. Jacobs, R. F., Tabor, D. R., Burks, A. W. & Campbell, G. D. Elevated interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 140, 1686-1692 (1989).
47. Wilson, M. S. et al. Bleomycin and IL-1 beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207, 535-552 (2010).
48. Kolb, M., Margetts, P. J., Anthony, D. C., Pitossi, F. & Gauldie, J. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest. 107, 1529-1536 (2001).
49. Challa, A. A. & Stefanovic, B. A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol. Cell. Biol. 31, 3773-3789 (2011).
50. Shumaker, D. K. et al. The highly conserved nuclear lamin Ig-fold binds to PCNA: its role in DNA replication. J. Cell Biol. 181, 269-280 (2008).
51. Perlson, E. et al. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J. Mol. Biol. 364, 938-944 (2006).
52. Stevens, C. et al. The intermediate filament protein, vimentin, is a regulator of NOD2 activity. Gut 62, 695-707 (2013).
53. Dinsdale, D., Lee, J. C. & Peter, M. E. Intermediate filaments control the intracellular distribution of capases during apopptosis. Am. J. Pathol. 164, 395-407 (2004).
54. Byun, Y. et al. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death. Differ. 8, 443-450 (2001).
55. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
56. Nekrasova, O. E. et al. Vimentin intermediate filaments modulate the motility of mitochondria. Mol. Biol. Cell 22, 2282-2289 (2011).
57. Mor-Vaknin, N., Punturieri, A., Sitwala, K. & Markovitz, D. M. Vimentin is secreted by activated macrophages. Nat. Cell Biol. 5, 59-63 (2003).
58. Budinger, G. R. et al. Proapoptotic Bid is required for pulmonary fibrosis. Proc. Natl Acad. Sci. USA 103, 4604-4609 (2006).
59. Azzam, Z. S. et al. Norepinephrine increases alveolar fluid reabsorption and Na,K-ATPase activity. Am. J. Resp. Crit. Care Med. 170, 730-736 (2004).
60. Butler, J. P., Nakamura, M., Sasaki, H., Sasaki, T. & Takishima, T. Poissons' ratio of lung parenchyma and parenchymal interaction with bronchi. Jpn. J. Physiol. 36, 91-106 (1986).
61. Liu, F. et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J. Cell Biol. 190, 693-706 (2010).
62. Liu, R. M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid. Redox. Signal. 10, 303-319 (2008).
63. Barish, G. D. et al. A nuclear receptor atlas: macrophage activation. Mol. Endocrinol. 19, 2466-2477 (2005).
64. Sivaramakrishnan, S., Schneider, J. L., Sitikov, A., Goldman, R. D. & Ridge, K. M. Shear stress induced reorganization of the keratin intermediate filament network requires phosphorylation by protein kinase C zeta. Mol. Biol. Cell 20, 2755-2765 (2009).
65. Rogel, M. R. et al. Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. FASEB J. 25, 3873-3883 (2011).
66. Herrmann, H. et al. Structure and assembly properties of the intermediate filament protein vimentin: the role of its head, rod and tail domains. J. Mol. Biol. 264, 933-953 (1996).